Drug Profile

Dinalbuphine sebacate - Lumosa Therapeutics

Alternative Names: LT 1001; Naldebain; Naldebain ER injection; SDE; Sebocoyl dinalbuphine ester

Latest Information Update: 23 Aug 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Lumosa Therapeutics
Class Analgesics; Esters; Ethers; Morphinans; Opioid analgesics; Small molecules
Mechanism of Action Opioid kappa receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Marketed Pain

Most Recent Events

23 Aug 2023 No development reported - Preregistration for Pain in Switzerland (IM)
28 Feb 2023 No recent reports of development identified for phase-I development in Pain(In volunteers) in USA (IM, Injection)
18 May 2021 Camargo Pharmaceutical Services has been acquired by Premier Research Group

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com